Neuropsychiatric Disorders And Treatment Market Research Report- Forecast To 2030

Neuropsychiatric Disorders And Treatment Market Research Report, By Disorders (Degenerative Diseases, Neurotic Disorders, Psychosis And Others), By Treatments (Shock Treatment, Drug Treatment, Others) By End Users (Hospitals, Clinics, Research Centers And Others) - Forecast Till 2030

ID: MRFR/Pharma/0773-HCR | 80 Pages | Published By Kinjoll Dey on March 2023         

TABLE OF CONTENTS

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY DISORDERS

5.1 DEGENERATIVE DISEASES

5.2 NEUROTIC DISORDERS

5.3 PSYCHOSIS

5.4 OTHERS

6. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY TREATMENT

6.1 SHOCK TREATMENT

6.2 DRUG TREATMENT

6.3 OTHERS

7. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY END USER

7.1 HOSPITALS

7.2 CLINICS

7.3 RESEARCH CENTRES

7.4 OTHERS

8. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY REGION

8.1 INTRODUCTION

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 WESTERN EUROPE

8.3.1.1 GERMANY

8.3.1.2 FRANCE

8.3.1.3 ITALY

8.3.1.3 SPAIN

8.3.1.5 UK

8.3.1.6 REST OF WESTERN EUROPE

8.3.2 EASTERN EUROPE

8.4 ASIA

8.4.1 JAPAN

8.4.2 CHINA

8.4.3 INDIA

8.4.4 AUSTRALIA

8.4.5 REPUBLIC OF KOREA

8.5 REST OF ASIA-PACIFIC

8.6 MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

9.1.1 STRATEGIC PARTNERSHIP

9.1.2 MERGER & ACQUISITION

10 COMPANY PROFILE

10.1 ASTRAZENECA

10.1.1 OVERVIEW

10.1.2 PRODUCT OVERVIEW

10.1.3 FINANCIALS

10.1.4 KEY DEVELOPMENTS

10.2 GLAXOSMITHKLINE

10.2.1 OVERVIEW

10.2.2 PRODUCT OVERVIEW

10.2.3 FINANCIALS

10.2.4 KEY DEVELOPMENTS

10.3 UNIVERSAL HEALTH SERVICES INC

10.3.1 OVERVIEW

10.3.2 PRODUCT OVERVIEW

10.3.3 FINANCIALS

10.3.4 STRATEGY

10.3.5 KEY DEVELOPMENT

10.4 BOEHRINGER INGELHEIM GMBH

10.4.1 OVERVIEW

10.4.2 PRODUCT OVERVIEW

10.4.3 FINANCIALS

10.4.4 KEY DEVELOPMENTS

10.5 ELI LILLY

10.5.1 OVERVIEW

10.5.2 PRODUCT OVERVIEW

10.5.3 FINANCIALS

10.5.4 KEY DEVELOPMENTS

10.6 OTHERS

11 CONCLUSION

11.1 KEY FINDINGS

11.1.1 FROM CEO’S VIEWPOINT

11.1.2 UNMET NEEDS OF THE MARKET

11.2 KEY COMPANIES TO WATCH

11.3 PREDICTION OF INDUSTRY

12 APPENDIX